Coulter Partners places Chief Scientific Officer for Erytech.
Coulter Partners was delighted to partner once more with Erytech Pharma to secure the appointment of Dr. Alexander Scheer as Chief Scientific Officer. ERYTECH Pharma (Euronext Paris:ERYP) (Paris:ERYP) (ADR:EYRYY) is a French biopharmaceutical company developing ‘tumor starvation’ treatments for acute leukemia and other oncology indications with unmet medical needs.
|“Alexander brings a wealth of knowledge in leading global R&D and drug discovery across multiple disciplines and several therapeutic areas, which will be invaluable to us at this critical stage of our development. It was a pleasure to work with everyone at Coulter Partners once again – an outstanding search team, whose professionalism continues to impress us,” comments Gil Beyen, Chief Executive Officer and Chairman of the Board of ERYTECH Pharma.
Dr. Scheer has over 15 years of experience in R&D and the life science industry. Prior to joining ERYTECH, he served as the Head of Research at Pierre Fabre in France, focused primarily on oncology and central nervous system research, and also served as a Deputy Head of Research at Pierre Fabre. Prior to joining Pierre Fabre, Dr. Scheer served as a Director, Global Research Informatics & Knowledge Management R&D and Project Leader, Neglected Diseases at Merck Serono in Switzerland where, among other responsibilities, he led Merck’s program to develop drugs for neglected diseases in collaboration with the World Health Organization (WHO). He also served as Head of Molecular Screening and Cellular Pharmacology Department, Group Leader of Biochemical Pharmacology and Research Scientist at Serono. Dr. Scheer holds a B.Sc in Natural Sciences and M.Sc. in Chemistry, both from the University of Gottingen, and a Ph.D. in Chemistry and Biochemistry from the German Cancer Research Center.
Dr. Scheer adds, “Erytech’s ERYCAPS technology represents a novel approach to anti-cancer tumor starvation treatment. The company has demonstrated exceptional progress in preclinical and clinical development of multiple pipeline programs and I look forward to leading the company’s efforts to leverage the ERYCAPS platform towards new indications and product candidates.”